BridgeMD
New treatment option for Pleural Mesothelioma
Official title Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma
ClinicalTrials.gov ID: NCT05930665
What this study is testing
What is Cadonilimab+Bevacizumab+Pemetrexed+Carboplatin?
Cadonilimab+Bevacizumab+Pemetrexed+Carboplatin is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for pleural mesothelioma.
Also referred to as AK104.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Cadonilimab, a tetravalent bispecific antibody targeting PD-1 and CTLA-4, is designed to retain the efficacy benefit of combination of PD-1 and CTLA-4 and improve on the safety profile of the combination therapy. The aim of this study is to evaluate the efficacy and safety of cadonilimab in combination with bevacizumab and standard chemotherapy as first Line therapy in unresectable pleural mesothelioma.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Histologically confirmed pleural malignant mesothelioma not eligible for curative surgery
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
- No previous systemic anti-tumor treatment for advanced/metastatic disease
- Measurable disease as per mRECIST v1.1 for assessment of response in malignant pleural mesothelioma.
- Adequate haematological, renal and liver function. Key
You likely can't join if
- Primitive peritoneal, pericardial and tunica vaginalis testis mesothelioma.
- Active, untreated central nervous system (CNS) metastasis.
- Use of Chinese herbal medicine or immunomodulatory agents with anti-tumor indications within 14 days prior to the first dose of study treatment.
- Known active autoimmune diseases.
- Presence of other uncontrolled serious medical conditions.
The study team makes the final eligibility decision.
Where it's taking place
- Guangzhou, Guangdong, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Guangzhou, Guangdong, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.